---
document_datetime: 2024-09-20 09:49:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ninlaro-epar-all-authorised-presentations_en.pdf
document_name: ninlaro-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7932525
conversion_datetime: 2025-12-23 03:43:01.54782
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form   | Route of administration   | Immediate Packaging   | Pack size                  |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|----------------------------|
| EU/1/16/1094/001 | NINLARO           | 2.3 mg     | Capsule, hard         | Oral use                  | blister (PVC-alu/alu) | 3 x 1 capsules (unit dose) |
| EU/1/16/1094/002 | NINLARO           | 3 mg       | Capsule, hard         | Oral use                  | blister (PVC-alu/alu) | 3 x 1 capsules (unit dose) |
| EU/1/16/1094/003 | NINLARO           | 4 mg       | Capsule, hard         | Oral use                  | blister (PVC-alu/alu) | 3 x 1 capsules (unit dose) |